[1]
|
M. J. Teta, P. J. Mink, E. Lau, B. K. Sceurman and E. D. Foster, “US Mesothelioma Patterns 1973-2002: Indicators of Change and Insights into Background Rates,” European Journal of Cancer Prevention, Vol. 17, No. 6, 2008, pp. 525-534.
http://dx.doi.org/10.1097/CEJ.0b013e3282f0c0a2
|
[2]
|
R. T. Lin, K. Takahashi, A. Karjalainen, et al., “Ecological Association between Asbestos-Related Diseases and Historical Asbestos Consumption: An International Analysis,” Lancet, Vol. 369, No. 9564, 2007, pp. 844-849.
http://dx.doi.org/10.1016/S0140-6736(07)60412-7
|
[3]
|
A. Linton, J. Vardy, S. Clarke and N. van Zandwijk, “The Ticking Time-Bomb of Asbestos: Its Insidious Role in the Development of Malignant Mesothelioma,” Critical Reviews in Oncology/Hematology, Vol. 84, No. 2, 2012, pp. 200-201.
http://dx.doi.org/10.1016/j.critrevonc.2012.03.001
|
[4]
|
N. J. Olsen, P. J. Franklin, A. Reid, et al., “Increasing Incidence of Malignant Mesothelioma after Exposure to Asbestos During Home Maintenance and Renovation,” Medical Journal of Australia, Vol. 195, No. 5, 2011, pp. 271-274. http://dx.doi.org/10.5694/mja11.10125
|
[5]
|
D. W. Henderson, G. Reid, S. C. Kao, N. van Zandwijk and S. Klebe, “Challenges and Controversies in the Diagnosis of Mesothelioma: Part 1. Cytology-Only Diagnosis, Biopsies, Immunohistochemistry, Discrimination between Mesothelioma and Reactive Mesothelial Hyperplasia, and Biomarkers,” Journal of Clinical Pathology, Vol. 66, No. 10, 2013, pp. 847-853.
http://dx.doi.org/10.1136/jclinpath-2012-201303
|
[6]
|
D. Curran, T. Sahmoud, P. Therasse, et al., “Prognostic Factors in Patients with Pleural Mesothelioma: The European Organization for Research and Treatment of Cancer Experience,” Journal of Clinical Oncology, Vol. 16, No. 1, 1998, pp. 145-152.
|
[7]
|
J. G. Edwards, K. R. Abrams, J. N. Leverment, et al., “Prognostic Factors for Malignant Mesothelioma in 142 Patients: Validation of CALGB and EORTC Prognostic Scoring Systems,” Thorax, Vol. 55, No. 9, 2000, pp. 731-735. http://dx.doi.org/10.1136/thorax.55.9.731
|
[8]
|
S. M. Mikulski, J. J. Costanzi, N. J. Vogelzang, et al., “Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients with Unresectable Malignant Mesothelioma,” Journal of Clinical Oncology, Vol. 20, No. 1, 2002, pp. 274-281.
http://dx.doi.org/10.1200/JCO.20.1.274
|
[9]
|
N. van Zandwijk, G. Reid, A. Linton and S. Kao, “Radical Surgery for Malignant Pleural Mesothelioma: Have We Identified the Appropriate Selection Tools?” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 481-486.
|
[10]
|
V. Rusch, E. H. Baldini, R. Bueno, et al., “The Role of Surgical Cytoreduction in the Treatment of Malignant Pleural Mesothelioma: Meeting Summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass,” Journal of Thoracic and Cardiovascular Surgery, Vol. 145, No. 4, 2013, pp. 909-910. http://dx.doi.org/10.1016/j.jtcvs.2013.01.039
|
[11]
|
J. M. Thomas and A. I. Musani, “Malignant Pleural Effusions: A Review,” Clinics in Chest Medicine, Vol. 34, No. 3, 2013, pp. 459-471.
http://dx.doi.org/10.1016/j.ccm.2013.05.004
|
[12]
|
A. Levy, A. Assouline, S. Rivera, C. Chargari and P. Tai, “Role of Conservative (Palliative) Care-Only in the Management of Advanced Malignant Pleural Mesothelioma,” Anticancer Research, Vol. 32, No. 9, 2012, pp. 4025-4027.
|
[13]
|
N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, et al., “Phase III Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma,” Journal of Clinical Oncology, Vol. 21, No. 14, 2003, pp. 2636-2644.
http://dx.doi.org/10.1200/JCO. 2003.11.136
|
[14]
|
A. Scherpereel, P. Astoul, P. Baas, et al., “Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the Management of Malignant Pleural Mesothelioma,” European Respiratory Journal, Vol. 35, No. 3, 2010, pp. 479-495.
http://dx.doi.org/10.1183/0903 1936.00063109
|
[15]
|
National Cancer Comprehensive Network, “NCCN Clinical Practice Guidelines in Oncology, Malignant Pleural Mesothelioma, v 1.2014,” 2013.
http://www.nccn.org/professionals/physician_gls/f_guide lines.asp
|
[16]
|
British Thoracic Society Standards of Care Committee, “BTS Statement on Malignant Mesothelioma in the UK, 2007,” Thorax, Vol. 62, Suppl. 2, 2007, pp. ii1-ii19.
|
[17]
|
R. A. Stahel, W. Weder, Y. Lievens, et al., “Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 21, Suppl. 5, 2010. pp. v126-v128.
http://dx.doi.org/10.1093/annonc/mdq173
|
[18]
|
G. L. Ceresoli, P. A. Zucali, M. Mencoboni, et al., “Phase II Study of Pemetrexed plus Carboplatin in Malignant Pleural Mesothelioma,” Journal of Clinical Oncology, Vol. 24, No. 9, 2006, pp. 1443-1448.
http://dx.doi.org/10.1200/JCO.2005.04.3190
|
[19]
|
M. F. Muers, R. J. Stephens, P. Fisher, et al., “Active Symptom Control with or without Chemotherapy in the Treatment of Patients with Malignant Pleural Mesothelioma (MS01): A Multicentre Randomised Trial,” Lancet, Vol. 371, No. 9625, 2008, pp. 1685-1694.
http://dx.doi.org/10.1016/S0140-6736 (08)60727-8
|
[20]
|
E. A. Eisenhauer, W. K. Evans, N. Murray, et al., “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer, Vol. 45, No. 2, 2009, pp. 228-247.
http://dx.doi.org/10.1016/j.ejca.2008.10.026
|
[21]
|
A. S. Tsao, L. Garland, M. Redman, et al., “A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria,” Journal of Thoracic Oncology, Vol. 6, No. 3, 2011, pp. 598-560.
http://dx.doi.org/10.1097/JTO.0b013e31820 8c83d
|
[22]
|
E. G. Butchart, T. Ashcroft, W. C. Barnsley and M. P. Holden, “Pleuropneumonectomy in the Management of Diffuse Malignant Mesothelioma of the Pleura. Experience with 29 Patients,” Thorax, Vol. 31, No. 1, 1976, pp. 15-24. http://dx.doi.org/10.1136/thx.31.1.15
|
[23]
|
D. Rice, “Standardizing Surgical Treatment in Malignant Pleural Mesothelioma,” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 497-501.
|
[24]
|
P. E. van Schil, P. Baas, R. Gaafar, et al., “Trimodality Therapy for Malignant Pleural Mesothelioma: Results from an EORTC Phase II Multicentre Trial,” European Respiratory Journal, Vol. 36, No. 6, 2010, pp. 1362-1369. http://dx.doi.org/10.1183/09031936.00039510
|
[25]
|
T. Treasure, L. Lang-Lazdunski, D. Waller, et al., “ExtraPleural Pneumonectomy versus No Extra-Pleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma: Clinical Outcomes of the Mesothelioma and Radical Surgery (MARS) Randomised Feasibility Study,” Lancet Oncology, Vol. 12, No. 8, 2011, pp. 763-772.
http://dx.doi.org/10.1016/S1470-2045(11)70149-8
|
[26]
|
V. W. Rusch, K. Rosenzweig, E. Venkatraman, et al., “A Phase II Trial of Surgical Resection and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma,” Journal of Thoracic and Cardiovascular Surgery, Vol. 122, No. 4, 2001, pp. 788-795.
http://dx.doi.org/10.1067/mtc. 2001.116560
|
[27]
|
V. Gupta, L. M. Krug, B. Laser, et al., “Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma after Extrapleural Pneumonectomy and Photon-Electron Radiotherapy,” Journal of Thoracic Oncology, Vol. 4, No. 6, 2009, pp. 746-750.
http://dx.doi.org/10.1097/JTO.0b013e3181 a5292c
|
[28]
|
ClinicalTrials.gov, 2013.
http://clinicaltrials.gov/ct2/results?term=mesothelioma
|
[29]
|
J. S. Friedberg, “Radical Pleurectomy and Photodynamic Therapy for Malignant Pleural Mesothelioma,” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 472-480.
|
[30]
|
J. S. Friedberg, M. J. Culligan, R. Mick, et al., “Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma,” Annals of Thoracic Surgery, Vol. 93, No. 5, 2012, pp. 1658-1665.
http://dx.doi.org/10.1016/j.athoracsur.2012.02.009
|
[31]
|
V. Rusch, L. Saltz, E. Venkatraman, et al., “A Phase II Trial of Pleurectomy/Decortication Followed by Intrapleural and Systemic Chemotherapy for Malignant Pleural Mesothelioma,” Journal of Clinical Oncology, Vol. 12, No. 6, 1994, pp. 1156-1163.
|
[32]
|
P. H. Sugarbaker, O. A. Stuart and C. Eger, “Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy Following Pleurectomy and Decortication,” Gastroenterology Research and Practice, Vol. 2012, 2012, Article ID: 471205. http://dx.doi.org/10.1155/2012/471205
|
[33]
|
W. Weder and I. Opitz, “Multimodality Therapy for Malignant Pleural Mesothelioma,” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 502-507.
|
[34]
|
J. Villena-Vargas and P. S. Adusumilli, “Mesothelin-Targeted Immunotherapies for Malignant Pleural Mesothelioma,” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 466-471.
|
[35]
|
R. J. Kelly, E. Sharon, I. Pastan and R. Hassan, “Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development,” Molecular Cancer Therapeutics, Vol. 11, No. 3, 2012, pp. 517-525.
http://dx.doi.org/10.1158/1535-7163.MCT-11-0454
|
[36]
|
E. L. Kwak, Y. J. Bang, D. R. Camidge, et al., “Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer,” New England Journal of Medicine, Vol. 363, No. 18, 2010, pp. 1693-1703.
http://dx.doi.org/10.1056/NEJMoa1006448
|
[37]
|
A. K. Nowak, “Chemotherapy for Malignant Pleural Mesothelioma: A Review of Current Management and a Look to the Future,” Annals of Cardiothoracic Surgery, Vol. 1, No. 4, 2012, pp. 508-515.
|